更昔洛韦治疗新生儿先天性巨细胞病毒感染临床效果观察

Clinical efficacy observation of ganciclovir on neonatal congenital cytomegalovirus infection

目的观察更昔洛韦在治疗新生儿先天性巨细胞病毒(CMV)感染上的疗效。方法将69例先天性CMV感染患儿随机分成3组,更昔洛韦组及丙种球蛋白组各27例、对照组15例。更昔洛韦组在常规治疗基础上加用更昔洛韦,诱导阶段:5mg/kg,静脉泵入,2次/d,连用14d,维持阶段:5mg/kg,1次/d,连用7d。丙种球蛋白组在常规治疗及应用更昔洛韦基础上加用丙种球蛋白400mg/kg,1次/d,连续应用3d。对照组予以常规治疗。结果治疗结束后,对患儿临床表现、实验室检查结果进行比较,各治疗组与对照组比较差异有统计学意义(P<0.05)。结论应用更昔洛韦治疗先天性巨细胞病毒感染安全、有效、经济。

Objective To explore the efficacy of ganciclovir on neonatal congenital cytomegalovlrus （（~MV） mtectmn. Methods Sixty-nine patients infected with CMV were randomized into 3 groups, 27 each including routine treatment, Ganciclovir group were administered with additional ganciclovir, at dose of 5 mg/kg, iv., twice a day for 14 consecu- tive days in induction stage, followed by 5 mg/kg, once a day for 7 consecutive days. Gamma globulin group were ad- ministered with gamma globulin 400 mg/kg in combination with ganciclovir and routine therapy, one time a day for 3 consecutive days. 15 patients in control group received routine therapy alone. Results Statistical difference was found between each therapeutic group and control group in clinical manifestations, laboratory routine tests and outcome showing virus infection （P 〈 0.05）. Conclusion Ganeiclovir for congenital CMV infection is safety, efficacy and economy.